Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOELAL02: Interferon Alpha-2a Maintenance in Adult ALL
NCT00483132Phase 3Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Sep 1994
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2a in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (4 arms), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Overall Survival. Started Sep 1994; status: completed.
02
Drugs
interferon alfa-2a
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00483132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483132.